


Claims:

1. A topical pharmaceutical composition comprising a lavendustin derivative of formula I



wherein R is methyl, methoxy or ethyl, or a pharmaceutically acceptable salt thereof, and an emollient.

2. A composition according to claim 1 wherein the emollient is isopropyl myristate.
3. A composition according to claim 1 in the form of an emulsion.
4. A composition according to claim 3 in the form of an oil-in-water emulsion.
5. A topical pharmaceutical composition according to any one of claims 1 to 4 which avoids high local concentration of the lavendustin in the skin or mucous membrane and is well tolerated.
6. A process for the preparation of a composition according to claim 1, comprising dissolving a lavendustin derivative of formula I as defined in claim 1, or a pharmaceutically acceptable salt thereof, in emollient and optionally further lipophilic components such as consistency agents, if present, preferably at elevated temperature, e.g. at from about 60 to about 80 °C, and adding the water phase, if present, under stirring and homogenization.
7. A composition according to any one of claims 1 to 4 for use in the treatment of hyperproliferative disorders such as actinic keratosis, anogenital warts and seborrhoic keratosis, and skin cancer.

8. Use of a composition according to any one of claims 1 to 4 in the preparation of a medicament for the treatment of hyperproliferative disorders such as actinic keratosis, anogenital warts and seborrhoic keratosis, and skin cancer.
9. A method of treatment of hyperproliferative disorders such as actinic keratosis, anogenital warts and seborrhoic keratosis, and skin cancer comprising administering a composition according to any one of claims 1 to 4 to the skin or mucous membrane of a patient in need thereof.